ScreenPoint Medical showcases Transpara Breast AI suite at RSNA 2025

Summary

Dutch firm ScreenPoint Medical is using RSNA 2025 to present new clinical evidence and deployments of its Transpara Breast AI suite, which supports detection, density assessment and risk prediction in screening mammography. The company reports that Transpara has now processed over 11 million mammograms across 30+ countries and is included in major randomized controlled trials such as Sweden's MASAI and the upcoming US PRISM study, underscoring the growing role of breast imaging AI in earlier cancer detection and workload reduction.